ADIA on OTC
Adia Med, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with AKANDA CORP., TFA Therapeutics, Inc. or China Foods Holdings Ltd., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
27.4%Gross margin3
-52.3%Operating margin3
-56.5%Net margin3
10879.7%Revenue growth, 20253
-$192.4KFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Sales Of Biologics brought in 37% of the revenue Adia Med, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Sales Of Biologics | $0 | $443.8K |
| Biologics | $0 | $289.6K |
| Medical Procedures | $0 | $245.6K |
| Procedures | $0 | $218.0K |
| Shipping And Delivery | $0 | $5.1K |
| Sales Of Supplements | $6.4K | $3.4K |
| Supplements | $4.2K | $1.3K |
| Sales Of Ancillary Products | $0 | $360 |
Business segments
Adia Labs brought in 64% of the revenue Adia Med, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2024 | 2025 |
|---|---|---|
| Adia Labs | $0 | $448.9K |
| Adia Med | $0 | $246.0K |
| Biolete | $6.4K | $3.4K |
| Corporate | $0 | $2.3K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue73¢$508.8K
- Research and development4¢$29.1K
- Other costs23¢$162.5K
Out of $700.5K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $700.5K | $6.4K |
| Total Cost of Revenue | $508.8K | $4.2K |
| Gross Profit | $191.7K | $2.2K |
| General and administrative | $51.4K | $30.0K |
| Advertising and promotion | $78.2K | $36.5K |
| Clinical trial fees | $6.9K | $0 |
| Corporate filings | $18.5K | $0 |
| Equipment leases | $31.8K | $0 |
| Legal and professional fees | $138.0K | $68.6K |
| Licenses | $2.7K | $0 |
| Public relations | $16.8K | $0 |
| Repairs and maintenance | $5.3K | $0 |
| Research and development | $29.1K | $0 |
| Rent | $64.6K | $10.6K |
| Salaries and wages | $61.8K | $0 |
| Shared-based compensation | $42.2K | $30.9K |
| Utilities | $6.3K | $0 |
| Depreciation and amortization | $4.4K | $433 |
| Total Operating Expenses | $558.2K | $176.9K |
| Profit (Loss) from Operations | -$366.5K | -$174.7K |
| Interest income | $625 | $0 |
| Sublease income | $2.0K | $0 |
| Interest expense line of credit (related party) | -$31.6K | -$6.3K |
| Total Other Income (Expense) | -$29.0K | -$6.3K |
| Net Loss Before Provision for Income Taxes | -$395.5K | -$181.1K |
| Provision for Income Taxes | $0 | $0 |
| NET LOSS | -$395.5K | -$181.1K |
| Net Loss Per Share: Basic | $0.00 | $0.00 |
| Net Loss Per Share: Diluted | $0.00 | $0.00 |
| Weighted Average Number of Shares Outstanding: Basic | 93.6M shares | 91.7M shares |
| Weighted Average Number of Shares Outstanding: Diluted | 93.6M shares | 91.7M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $79.4K | $6.3K | |
| Accounts receivable | $33.4K | $0 | |
| Accrued interest due | $250 | $0 | |
| Pre-paid inventory | $25.0K | $206.9K | |
| Prepaid expenses | $23.5K | $45.2K | |
| Total Current Assets | $161.5K | $258.4K | |
| Investment in non-consolidated entity | $79.5K | $79.5K | |
| Receivable on sale of inventory asset | $72.1K | $0 | |
| Start-up clinic loans | $25.0K | $0 | |
| Intangible assets trademarks, net of amortization | $0 | $5.9K | |
| Deposits | $10.0K | $10.0K | |
| Fixed assets, net of depreciation | $30.7K | $21.6K | |
| Finance lease, net | $108.2K | $130.3K | |
| Right of use asset - operating lease, net | $107.8K | $160.4K | |
| Total Non Current Assets | $433.3K | $407.8K | |
| Total Assets | $594.8K | $666.2K | |
| Accounts payable | $2.4K | $4.9K | |
| Payroll liabilities | $153 | $0 | |
| Accrued interest related party | $37.9K | $6.3K | |
| Deferred revenue | $14.0K | $0 | |
| Operating | $64.0K | $51.5K | |
| Finance | $26.8K | $17.3K | |
| Total Current Liabilities | $145.2K | $80.0K | |
| Line of credit | $600.0K | $368.5K | |
| Operating | $45.9K | $104.1K | |
| Finance | $61.4K | $88.0K | |
| Total Non Current Liabilities | $707.3K | $560.6K | |
| Total Liabilities | $852.5K | $640.6K | |
| Shares to be issued | $152.6K | $110.4K | |
| Additional paid-in capital | $15.5M | $15.4M | |
| Accumulated deficit | -$16.0M | -$15.6M | |
| Total Stockholders' Equity (Deficit) | -$257.7K | $25.5K | -$750 |
| Total Liabilities and Stockholders Equity (Deficit) | $594.8K | $666.2K |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$395.5K | -$181.1K |
| Depreciation and amortization | $4.1K | $433 |
| Amortization of right of use asset - operating | $52.6K | $8.4K |
| Amortization of right-of-use asset - financing | $22.1K | $0 |
| Gain on sale of intangible assets | -$239 | $0 |
| Share-based compensation | $42.2K | $30.9K |
| Accounts receivable | -$33.4K | $0 |
| Accrued interest receivable | -$250 | $0 |
| Deposits | $0 | -$10.0K |
| Prepaid expenses | $161.0K | -$45.2K |
| Inventory | -$29.5K | -$136.9K |
| Accounts payable | -$2.5K | $4.9K |
| Payroll liabilities | $153 | $0 |
| Accrued interest line of credit | $31.6K | $6.3K |
| Deferred revenue | $14.0K | $0 |
| Lease liability - operating | -$45.8K | -$13.2K |
| Net Cash Used for Operating Activities | -$179.2K | -$335.5K |
| Purchase of furniture & equipment | -$13.2K | -$21.8K |
| Purchase of intangible assets | $0 | -$4.1K |
| Sale of intangible assets | $6.1K | $0 |
| Loans to start-up clinics | -$25.0K | $0 |
| Net Used for Investing Activities | -$32.1K | -$26.0K |
| Payments made on lease liability - finance | -$17.1K | -$25.0K |
| Line of credit | $231.5K | $367.3K |
| Proceeds from sales of common stock | $70.0K | $25.0K |
| Net Cash Provided by Financing Activities | $284.3K | $367.3K |
| Net Increase in Cash | $73.1K | $5.8K |
| Cash paid for interest | $0 | $0 |
| Cash paid for taxes | $0 | $0 |
| Shares to be issued for investment in non-consolidated business entity | $0 | $79.5K |
| Shares issued for acquisition of Biolete, LLC | $0 | $72.0K |
| Receivable on sale of inventory asset | $72.1K | $0 |
| Operating right-of-use asset obtained though operating lease obligation | $0 | $168.8K |
| Finance right-of-use asset obtained through finance lease obligation | $0 | $130.3K |
| Cancellation of shares | $25.5K | $0 |
Former names
Recent filings
- Oct 13, 20268-K CURRENT REPORT
- Oct 6, 20268-K CURRENT REPORT
- Oct 5, 20268-K CURRENT REPORT
- Aug 24, 20268-K CURRENT REPORT
- Aug 17, 20268-K CURRENT REPORT
- Aug 13, 202610-Q FORM 10-Q FOR JUN 2026
- May 15, 202610-Q FORM 10-Q FOR MAR 2026
- Mar 31, 202610-K FORM 10-K FOR DEC 2025
- Dec 5, 202510-12G FORM 10-12(G)
- Jun 24, 2024253G1
- Jun 21, 2024QUALIF
- Jun 18, 20241-A/A
- Jun 18, 2024CORRESP
- Jun 18, 2024CORRESP
- Jun 10, 20241-A/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAdia Med, Inc. filings on SEC EDGAR
- 2SEC EDGARAdia Med, Inc. filings on SEC EDGAR
- 3SEC EDGARAdia Med, Inc. 10-K for fiscal 2025
- 4SEC EDGARAdia Med, Inc. 10-Q for fiscal 2025
- 5SEC EDGARAdia Med, Inc. 10-Q for fiscal 2026